Workshop C: Building a Sustainable Business Model for Rare Kidney Disease Therapies

This workshop is designed for business development professionals, biotech leaders, market access teams, and clinical development strategists working to strengthen the commercialization foundations of rare kidney disease therapies. While scientific innovation in nephrology is accelerating, many programs struggle to translate clinical success into sustainable reimbursement and investment due to misalignment between development strategies and payer expectations.

This session will explore how clinical evidence and value demonstration can be aligned earlier in development to support stronger market access and investment readiness, helping teams integrate commercialization thinking across the developmental lifecycle.

Dive into:

• Understanding payer and HTA expectations and how these should inform evidence generation, endpoint selection, and clinical trial design
• Developing value frameworks for rare kidney disease therapies, including how to articulate clinical and economic value to payers
• Building the strategic skills to evaluate commercialization viability early, helping teams align clinical development decisions with reimbursement and investment considerations

Speakers:

Srini Srinivas

Senior Medical Director

Novartis

Manish Maski

Global Medical Affairs Exec Director

Vertex Pharmaceuticals